Showing results (51-60 of 85) with videos related to
Sort By:
Pageof 9
Journal of Medicinal Chemistry|April 1, 1986
Quinazoline antifolates inhibiting thymidylate synthase: benzoyl ring modificationsT R Jones, M J Smithers, M A Taylor, et al.British Journal of Urology|August 1, 1992
Initial combination chemotherapy with cisplatin, methotrexate and vinblastine in locally advanced transitional cell carcinoma--response rate and pitfalls. MRC Subgroup in Advanced Bladder Cancer (on behalf of the MRC Urological Working Party)S D Fosså, S J Harland, S B Kaye, et al.The Journal of Urology|September 29, 1998
Intratubular germ cell neoplasia of the contralateral testis in testicular cancer: defining a high risk groupS J Harland, P A Cook, S D Fossa, et al.European Journal of Clinical Pharmacology|January 1, 1987
Prescribing digoxin in geriatric units: the unexplained variability in dosage requirementsR J Dobbs, J P Royston, C J O'Neill, et al.British Journal of Clinical Pharmacology|October 1, 1988
The paradox of using a 7 day antibacterial course to treat urinary tract infections in the communityR Cheung, C M Sullens, D Seal, et al.European Journal of Clinical Pharmacology|January 1, 1991
Effect of duration of levodopa/decarboxylase inhibitor therapy on the pharmacokinetic handling of levodopa in elderly patients with idiopathic Parkinson's diseaseS G Bowes, C J O'Neill, P W Nicholson, et al.Acta Neurologica Scandinavica|April 1, 1993
Assessment of the bradyphrenia of parkinsonism: a novel use of delayed auditory feedbackR J Dobbs, S G Bowes, M Henley, et al.European Journal of Clinical Pharmacology|March 1, 1981
Evaluation of medigoxin in outpatientsW R Smith, E M Rodgers, P W Nicholson, et al.British Journal of Clinical Pharmacology|April 1, 1993
Defining small differences in efficacy between anti-parkinsonian agents using gait analysis: a comparison of two controlled release formulations of levodopa/decarboxylase inhibitorC Weller, C J O'Neill, A Charlett, et al.British Journal of Cancer|March 18, 2004
Paclitaxel-containing high-dose chemotherapy for relapsed or refractory testicular germ cell tumoursI A McNeish, E J Kanfer, R Haynes, et al.Pageof 9